208 related articles for article (PubMed ID: 29133095)
1. Carboxymethyl dextran-based hypoxia-responsive nanoparticles for doxorubicin delivery.
Son S; Rao NV; Ko H; Shin S; Jeon J; Han HS; Nguyen VQ; Thambi T; Suh YD; Park JH
Int J Biol Macromol; 2018 Apr; 110():399-405. PubMed ID: 29133095
[TBL] [Abstract][Full Text] [Related]
2. Anti-Trop2 antibody-conjugated bioreducible nanoparticles for targeted triple negative breast cancer therapy.
Son S; Shin S; Rao NV; Um W; Jeon J; Ko H; Deepagan VG; Kwon S; Lee JY; Park JH
Int J Biol Macromol; 2018 Apr; 110():406-415. PubMed ID: 29055700
[TBL] [Abstract][Full Text] [Related]
3. Hyaluronic Acid Derived Hypoxia-Sensitive Nanocarrier for Tumor Targeted Drug Delivery.
Le TN; Lin CJ; Shen YC; Lin KY; Lee CK; Huang CC; Rao NV
ACS Appl Bio Mater; 2021 Dec; 4(12):8325-8332. PubMed ID: 35005953
[TBL] [Abstract][Full Text] [Related]
4. Bioreducible carboxymethyl dextran nanoparticles for tumor-targeted drug delivery.
Thambi T; You DG; Han HS; Deepagan VG; Jeon SM; Suh YD; Choi KY; Kim K; Kwon IC; Yi GR; Lee JY; Lee DS; Park JH
Adv Healthc Mater; 2014 Nov; 3(11):1829-38. PubMed ID: 24753360
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia-responsive polymeric nanoparticles for tumor-targeted drug delivery.
Thambi T; Deepagan VG; Yoon HY; Han HS; Kim SH; Son S; Jo DG; Ahn CH; Suh YD; Kim K; Kwon IC; Lee DS; Park JH
Biomaterials; 2014 Feb; 35(5):1735-43. PubMed ID: 24290696
[TBL] [Abstract][Full Text] [Related]
6. Carboxymethyl dextran-cyclodextrin conjugate as the carrier of doxorubicin.
Sivasubramanian M; Thambi T; Deepagan VG; Saravanakumar G; Ko H; Kang YM; Park JH
J Nanosci Nanotechnol; 2013 Nov; 13(11):7271-8. PubMed ID: 24245242
[TBL] [Abstract][Full Text] [Related]
7. Rational Design of Nanoparticles to Overcome Poor Tumor Penetration and Hypoxia-Induced Chemotherapy Resistance: Combination of Optimizing Size and Self-Inducing High Level of Reactive Oxygen Species.
Deng L; Feng Z; Deng H; Jiang Y; Song K; Shi Y; Liu S; Zhang J; Bai S; Qin Z; Dong A
ACS Appl Mater Interfaces; 2019 Sep; 11(35):31743-31754. PubMed ID: 31389686
[TBL] [Abstract][Full Text] [Related]
8. Programmed pH/reduction-responsive nanoparticles for efficient delivery of antitumor agents in vivo.
Chen WL; Yang SD; Li F; Qu CX; Liu Y; Wang Y; Wang DD; Zhang XN
Acta Biomater; 2018 Nov; 81():219-230. PubMed ID: 30267887
[TBL] [Abstract][Full Text] [Related]
9. Enhanced tumor delivery and antitumor response of doxorubicin-loaded albumin nanoparticles formulated based on a Schiff base.
Li F; Zheng C; Xin J; Chen F; Ling H; Sun L; Webster TJ; Ming X; Liu J
Int J Nanomedicine; 2016; 11():3875-90. PubMed ID: 27574421
[TBL] [Abstract][Full Text] [Related]
10. Zwitterionic mesoporous nanoparticles with a bioresponsive gatekeeper for cancer therapy.
Khatoon S; Han HS; Lee M; Lee H; Jung DW; Thambi T; Ikram M; Kang YM; Yi GR; Park JH
Acta Biomater; 2016 Aug; 40():282-292. PubMed ID: 27063494
[TBL] [Abstract][Full Text] [Related]
11. pH and redox dual-sensitive polysaccharide nanoparticles for the efficient delivery of doxorubicin.
Yang S; Tang Z; Zhang D; Deng M; Chen X
Biomater Sci; 2017 Sep; 5(10):2169-2178. PubMed ID: 28914292
[TBL] [Abstract][Full Text] [Related]
12. Reduction Responsive Self-Assembled Nanoparticles Based on Disulfide-Linked Drug-Drug Conjugate with High Drug Loading and Antitumor Efficacy.
Song Q; Wang X; Wang Y; Liang Y; Zhou Y; Song X; He B; Zhang H; Dai W; Wang X; Zhang Q
Mol Pharm; 2016 Jan; 13(1):190-201. PubMed ID: 26629710
[TBL] [Abstract][Full Text] [Related]
13. A pH-responsive carboxymethyl dextran-based conjugate as a carrier of docetaxel for cancer therapy.
Han HS; Lee M; An JY; Son S; Ko H; Lee H; Chae YS; Kang YM; Park JH
J Biomed Mater Res B Appl Biomater; 2016 May; 104(4):789-96. PubMed ID: 26687579
[TBL] [Abstract][Full Text] [Related]
14. Zwitterionic pH/redox nanoparticles based on dextran as drug carriers for enhancing tumor intercellular uptake of doxorubicin.
Wu L; Zhang L; Shi G; Ni C
Mater Sci Eng C Mater Biol Appl; 2016 Apr; 61():278-85. PubMed ID: 26838851
[TBL] [Abstract][Full Text] [Related]
15. Tumor targeting efficiency of bare nanoparticles does not mean the efficacy of loaded anticancer drugs: importance of radionuclide imaging for optimization of highly selective tumor targeting polymeric nanoparticles with or without drug.
Lee BS; Park K; Park S; Kim GC; Kim HJ; Lee S; Kil H; Oh SJ; Chi D; Kim K; Choi K; Kwon IC; Kim SY
J Control Release; 2010 Oct; 147(2):253-60. PubMed ID: 20624433
[TBL] [Abstract][Full Text] [Related]
16. Optical Properties of Doxorubicin Hydrochloride Load and Release on Silica Nanoparticle Platform.
Nguyen TN; Nguyen TT; Nghiem THL; Nguyen DT; Tran TTH; Vu D; Nguyen TBN; Nguyen TMH; Nguyen VT; Nguyen MH
Molecules; 2021 Jun; 26(13):. PubMed ID: 34209621
[TBL] [Abstract][Full Text] [Related]
17. Redox-Responsive Amphipathic Dextran Nanomicelles for Solid Tumor Therapy.
Song Y; Lou B; Cheng J; Zhao P; Lin C; Wen X
J Biomed Nanotechnol; 2016 Dec; 12(12):2083-96. PubMed ID: 29368837
[TBL] [Abstract][Full Text] [Related]
18. Chemosensitizing indomethacin-conjugated chitosan oligosaccharide nanoparticles for tumor-targeted drug delivery.
Lee JY; Termsarasab U; Lee MY; Kim DH; Lee SY; Kim JS; Cho HJ; Kim DD
Acta Biomater; 2017 Jul; 57():262-273. PubMed ID: 28483700
[TBL] [Abstract][Full Text] [Related]
19. Doxorubicin Intracellular Release
El Founi M; Laroui H; Canup BSB; Ametepe JS; Vanderesse R; Acherar S; Babin J; Ferji K; Chevalot I; Six JL
ACS Appl Bio Mater; 2021 Mar; 4(3):2742-2751. PubMed ID: 35014313
[TBL] [Abstract][Full Text] [Related]
20. Robust PEGylated hyaluronic acid nanoparticles as the carrier of doxorubicin: mineralization and its effect on tumor targetability in vivo.
Han HS; Lee J; Kim HR; Chae SY; Kim M; Saravanakumar G; Yoon HY; You DG; Ko H; Kim K; Kwon IC; Park JC; Park JH
J Control Release; 2013 Jun; 168(2):105-14. PubMed ID: 23474029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
